InsidersTradesSigma
Track the 瑞普生物 share price and the full directors' dealings record of the company, a listed issuer based in China. Shares are quoted on the CN market, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 瑞普生物 has published 2 reports. Market capitalisation: €8.5bn. The latest transaction was filed on 16 June 2026 (Purchase). Among the most active insiders: 徐雷. Every trade is openly available.
Analysts rate 瑞普生物 Buy (bullish), based on 3 analysts. Average price target: CN¥20.41.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
瑞普生物是一家专注于健康和制药领域的公司，专门从事生物制药解决方案的研发。该公司在XSHE市场上市。